

SEQUENCE LISTING

<110> BioNTech RNA Pharmaceuticals GmbH

<120> Selecting Neoepitopes as Disease-Specific Targets for Therapy
with Enhanced Efficacy

<130> 755-2 PCT2

<140> PCT/EP2017/068226

<141> 2017-07-19

<150> PCT/EP2016/067348

<151> 2016-07-20

<160> 2

<170> PatentIn version 3.5

<210> 1

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Linker sequence

<220>

<221> REPEAT

<222> (1)..(3)

<223> Portion of sequence repeated a times, wherein a is independently
a number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, or 20

<220>

<221> MISC_FEATURE

<222> (1)..(15)

<223> a + b + c + d + e are different from 0 and preferably are 2 or
more, 3 or more, 4 or more or 5 or more

<220>

<221> REPEAT

<222> (4)..(6)

<223> Portion of sequence repeated b times, wherein b is independently
a number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, or 20

<220>

<221> REPEAT

<222> (7)..(9)

<223> Portion of sequence repeated c times, wherein c is independently
a number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, or 20

<220>

<221> REPEAT

<222> (10)..(12)

<223> Portion of sequence repeated d times, wherein d is independently
a number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, or 20

<220>

<221> REPEAT
<222> (13)..(15)
<223> Portion of sequence repeated e times, wherein e is independently
a number selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12,
13, 14, 15, 16, 17, 18, 19, or 20

<400> 1

Gly Gly Ser Gly Ser Ser Gly Gly Gly Ser Ser Gly Gly Ser Gly
1 5 10 15

<210> 2
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> linker sequence

<400> 2

Gly Gly Ser Gly Gly Gly Gly Ser Gly
1 5